Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Sep 23 - Sep 28
Wang, J
Ozempic is a GLP-1 receptor agonist licensed in the UK for type 2 diabetes, administered as a once-weekly subcutaneous injection
it is presented as scientific record only and is not a clinical or human-use claim for IDUNs product
Lancet 365: 15611569
Under the action of unhealthy metabolic factors (obesity, diabetes), ER stress is initiated, and IRE-1 is activated, which in turn leads to the phosphorylation of IRS1 at the serine 307 residue by activating JNK, thereby impairing insulin signaling
Key Research Properties: Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor Modulates NAD+ metabolism and methylation capacity Studied in context of energy expenditure and metabolic regulation NNMT is upregulated in obesity
US$ 25.84
US$ 21.42
US$ 20.52
US$ 22.69
